Core Viewpoint - Jinxin Reproductive Medicine (01951) is experiencing a decline in stock price, currently down over 4%, with a trading price of HKD 3.25 and a transaction volume of HKD 118 million. The company has issued a profit warning, expecting a loss of no more than RMB 1.09 billion for the first half of the year, compared to a profit of RMB 190 million in the same period last year. The anticipated loss is primarily due to impairment and provisions related to goodwill, intangible assets, and other financial assets in its operations in the United States and Laos [1][1][1]. Company Summary - Jinxin Reproductive Medicine's stock price has dropped by 3.85% as of the latest report [1]. - The company plans to review its mid-year results for 2025 on August 25 [1]. - The expected loss of up to RMB 1.09 billion marks a significant decline from the previous year's profit of RMB 190 million [1]. - The primary reasons for the anticipated loss include impairments and provisions related to goodwill and intangible assets in its U.S. and Laos operations [1].
锦欣生殖现跌超4% 公司下周一将发业绩 此前预计上半年亏损不超10.9亿元